Medicare’s annual limit on out-of-pocket prescription drug spending is rising to $2,400 in 2027, a $300 increase over this year’s $2,100 ceiling. The Centers for Medicare & Medicaid Services finalized the new figure last spring as part of its yearly Part D rate-setting process, alongside a separate jump in the standard deductible. For beneficiaries managing an expensive brand-name prescription, that extra $300 is the difference between hitting the point where covered drug costs stop and paying full price for several more weeks.
How the 2027 Cap Fits Into Part D’s Structure
Part D coverage moves beneficiaries through three stages in a given year: the annual deductible, the initial coverage period, and the catastrophic phase, where the plan picks up the entire remaining bill. Every dollar spent on covered drugs — whether it goes toward the deductible, a copay, or coinsurance — counts toward a single running total known as true out-of-pocket costs, or TrOOP. Once that total hits the annual ceiling, the beneficiary owes nothing more for covered prescriptions through December 31.
According to UnitedHealthcare’s guidance on the 2027 changes, the out-of-pocket maximum for Part D prescription drugs is set at $2,400 for the coming year, up from $2,100 now. That number resets every January 1 no matter how quickly a costly diagnosis or a new specialty prescription pushes someone toward it, and it carries over automatically if a beneficiary switches plans mid-year, with the new plan picking up wherever the old one left off.
The deductible increase arriving the same year does not sit on top of that total. Reporting noted that Medicare’s 2027 Part D deductible is climbing to $700 from $615, and that the $700 counts toward the $2,400 ceiling rather than being added to it. Some plans reduce or waive the standard deductible altogether, applying it only to higher-cost drug tiers, which means two people with the same diagnosis can face very different January bills depending on which plan they picked during open enrollment.
Before 2025, Part D had no true ceiling at all. The Inflation Reduction Act created Medicare’s first hard cap on out-of-pocket drug costs, phasing it in gradually so the number has risen each year since — a trajectory that continues with the jump to $2,400 for 2027. For someone on a handful of specialty medications, that history matters less than the current math: whatever a plan’s deductible and coinsurance structure look like, $2,400 is the absolute ceiling once TrOOP spending gets there.
Free retirement updates: A quiet rule change can shrink your Social Security or Medicare check, and no one warns you. The free Retirement Shield newsletter catches these early and tells you what to do. Get it free.
Why the Numbers Keep Climbing Each Year
CMS finalizes both the deductible and the out-of-pocket threshold every spring through the announcement finalizing 2027 Part D payment policy, using a statutory formula tied to growth in prescription drug spending across the entire Part D program. The agency locked in both the $700 deductible and the $2,400 cap months before insurers finalize next year’s plan designs, giving carriers a fixed target to build premiums and formularies around.
That formula does not ask whether a given beneficiary can absorb the increase; it simply tracks what the program as a whole is spending on covered drugs. As brand-name specialty medications continue driving overall Part D costs higher, the indexed cap moves in the same direction, regardless of whether an individual retiree’s own prescriptions changed at all, and regardless of income, since the standard benefit design applies the same dollar figure to every enrollee.
The deductible and the ceiling do not always move at the same pace, either. The $85 jump in the deductible is proportionally larger than the increase to the annual cap, which means beneficiaries who fill only a handful of low-cost generics may notice the deductible change more than the ceiling, while those on expensive specialty drugs will feel both increases by midyear.
Reviewing Coverage Before Enrollment Closes December 7
Medicare’s annual open enrollment period, which runs from October 15 through December 7, is the one window each year to compare plans against the coming year’s numbers rather than assume last year’s coverage still fits. Letting a Part D plan renew automatically carries real risk, since drug tiers, pharmacy networks, and deductible structures can all shift for the new plan year even when the plan’s name and premium look unchanged.
Comparing total annual cost, not just the monthly premium, is what separates a retiree who reaches the $2,400 ceiling in September from one who never gets close. Entering every current prescription, dose, and preferred pharmacy into Medicare’s Plan Finder tool shows which plans apply the full deductible to a specific medication and which ones offer better first-fill pricing on the drugs a person actually takes.
For beneficiaries who anticipate a high-cost year, the Medicare Prescription Payment Plan offers another option: rather than paying the deductible and early-year coinsurance in a lump sum, enrollees can ask their plan to spread those costs into predictable monthly installments across the calendar year. It does not lower the $2,400 ceiling, but it can prevent a single January pharmacy trip from draining a fixed income in one transaction.
The $300 increase for 2027 is modest compared with what beneficiaries paid before the Inflation Reduction Act’s cap took hold, but it is real money for anyone managing a chronic condition on a fixed budget. Reviewing the Annual Notice of Change letter that arrives every September, rather than setting it aside with the rest of the mail, remains the simplest way to know exactly where the new numbers leave a household before the bill ever arrives.
This article was produced with the assistance of AI and reviewed by The Money Overview editorial team before publication.
More Financial Reading
